

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF  
01 AUG 14 1

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Health Policy Alternatives, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 444 North Capitol St. NW, Suite 821			
3. Principal Place of Business (if different from line 2) City: Washington State/Zip (or Country) DC 20001			
4. Contact Name Thomas A. Ault		Telephone 202-737-3390	E-mail (optional) 5. Senate ID #
7. Client Name <input type="checkbox"/> Self Pharmaceutical Research & Manufacturers of America			6. House ID # 312620

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30)  OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  ⇒ Termination Date \_\_\_\_\_

11. No Lobbying

### INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

#### 12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000

\$10,000 or more  ⇒ \$ 60,000  
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000

\$10,000 or more  ⇒ \$ \_\_\_\_\_  
Expenses (nearest \$)

14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of

Method A. Reporting amounts using LDA definition

Method B. Reporting amounts under section 6033 Internal Revenue Code

Method C. Reporting amounts under section 162(c) Internal Revenue Code

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_



Registrant Name Health Policy Alternatives Client Name Pharmaceutical Research & Manufac

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide the following information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues


Technical assistance on various issues related to Medicare coverage and reimbursement of pharmaceuticals, including the Medicare outpatient PPS

17. House(s) of Congress and Federal agencies contacted  Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Thomas A. Ault	
Julia A. James	
Richard A. Lauderbaugh	

9. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature  Date August 14, 2001

Printed Name and Title Thomas A. Ault, Principal

